Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access
Team Inbeeo is ready for ISPOR Europe 2022 in Vienna.
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
